Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
A study published in the February issue of The American Journal of Managed Care® (AJMC®) was highlighted in an article in The Atlantic. The study, “Value-Based Arrangements May Be More Prevalent Than Assumed,” surveyed senior representatives from payer organizations and biopharmaceutical manufacturers to better understand the prevalence of value-based payment arrangements (VBAs) in the United States. The results showed that the majority of VBAs are not publicly disclosed, which could lead to underestimates of their true prevalence and impact.
An article from Genetic Engineering & Biotechnology News covered the panel discussion during AJMC®’s Institute for Value-Based Medicine held April 16 in White Plains, New York. During the panel discussion, “Advancing Quality Oncology Care in the Evolving Value-Based Care Landscape,” panelists discussed how payers are engaging with oncology providers in value-based care models, successfully managing high-risk patients, and more.
The National Pharmaceutical Council’s Tuesday CER Daily Newsfeed included the AJMC® article, “HHS Announces 5 New Primary Care Payment Models to Encourage Value-Based Care,” which covered the announcement from HHS Secretary Alex Azar and CMS Administrator Seema Verma that the administration is launching 5 new Medicare primary care payment models designed to eventually incentivize the entire healthcare system to transition to value-based care, particularly for patients with chronic conditions.
OBR Oncology’s Wednesday newsfeed included an article from AJMC®’s sister site The Center for Biosimilars®. The article, “Biosimilar Filgrastim Similar to Reference Product When Used in NSCLC,” covered new data from a subset analysis of MONITOR-GCSF, which showed that biosimilar filgrastim has similar effectiveness and safety to reference filgrastim.